Merck & Co., Inc. announced it has submitted a new drug application for Arcoxia (etoricoxib) to the US Food and Drug Administration (FDA). Merck's NDA seeks indications for Arcoxia for the treatment of osteoarthritis, rheumatoid arthritis, chronic low back pain, acute pain, dysmenorrhea, acute gouty arthritis and ankylosing spondylitis. Within the next 60 days, the FDA will determine whether it will accept Merck's application as submitted.

Arcoxia has been launched in 38 countries worldwide in Europe, Latin America and the Asia-Pacific region.

Merck & Co., Inc. is a global research-driven pharmaceutical products company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures.